跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NUCALA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NUCALA
Authorized
STANDARD
NUCALA
GlaxoSmithKline Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
bb92a857a99bbea4
Company
GlaxoSmithKline Inc
Type
Standard
Approval Details
Approval Id
bb92a857a99bbea4
Drug Approval Canada Name
NUCALA
Product Name
NUCALA
Status
Marketed
Status Date
2023-02-13
Original Market Date
2023-02-13
Din
02530821
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
90:28.00
Atc Original
R03DX09 MEPOLIZUMAB
Atc Name
r 03 dx 09
Aig Number
0157630001
Company Name
GlaxoSmithKline Inc
Company Address
800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path
/organization/glaxosmithkline-inc
Company Information
Pharmaceutical Company Name
GlaxoSmithKline Inc
Country Name
Canada
Province Name
Ontario
City Name
mississauga,ontario,country_ca
Address
800-100 Milverton Dr
Active Ingredients
MEPOLIZUMAB
40 MG / 0.4 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
bb92a857a99bbea4
Type
Standard
Back to Health Canada Approvals